Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Are Masp-2 levels after allo-HSCT associated with TMA development?

Jeffrey Laurence • 7 Dec 2019
ASH 2019
General

A dangerous potential complication of allo-HSCT is thrombotic microangiopathy (TMA). Jeffrey Laurence, MD, Weill Cornell Medical College, Greenwich, CT, discusses a study (NCT02604420) investigating the level of Masp-2, a key part of lectin-dependent complement activation, following allo-HSCT in adults and its correlation with the development of TMA, which may have implications for anti-complement therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Jeffrey Laurence

3:06
Defibrotide inhibits endothelial injury induced by plasmas of patients with TMA
Jeffrey Laurence • 7 Dec 2019

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals